Share
The official podcast of Rampver Financials. Delivering the best talks, advice, and recommendations about personal finance, investing, entrepreneurship, and success. Subscribe and never miss an episode!
…
continue reading
Manage episode 512645113 series 2986293
Content provided by STAT. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by STAT or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back?
We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on Mizuho health care strategist Jared Holz to discuss the rebound in biotech stocks and sentiment.
We also talk about Marks’ new role at Eli Lilly after leaving the Food and Drug Administration, an attempt by a biotech to revive a rare disease drug shelved by AstraZeneca, and new funds raised by China-focused Expedition Therapeutics.
377 episodes
))
